CARDOZA GEORGE 4/A

What Happened

• George Cardoza, Chief Financial Officer of SOPHiA GENETICS SA (SOPH), was granted equity awards on April 2, 2026. The filing shows 112,936 ordinary shares granted and 164,671 derivative awards (RSUs), both reported at $0 per share, for a total of 277,607 RSU‑type awards. This is an equity compensation award (not an open‑market purchase or sale).
• The grant is reported on an amended Form 4/A that corrects the amount of securities beneficially owned following the transaction to 297,794 ordinary shares (see footnote F2).

Key Details

• Transaction date: 2026-04-02; reported in an amended Form 4/A filed 2026-04-08 (original Form 4 was filed 2026-04-03).
• Reported amounts: 112,936 ordinary shares (acquired) and 164,671 derivative RSU awards (acquired) — total 277,607 awards; all reported at $0.00 per share.
• Shares beneficially owned following transaction: corrected to 297,794 ordinary shares (per F2).
• Vesting (footnotes): F1 — RSUs granted under the 2021 Equity Incentive Plan; 25% vest on April 2, 2027, remainder vests in equal quarterly installments through April 2, 2030. F3 notes a vesting schedule for related share options (25% on April 2, 2027, then in monthly installments) as included in the filing. F2 explains this filing amends the Apr 3 Form 4 to correct the ownership number.
• Filing status: This is an amended Form 4/A correcting previously reported ownership; the original Form 4 was filed April 3, 2026.

Context

• These are time‑based RSU awards (compensation) that vest over multiple years and do not represent an immediate cash purchase or sale. They are contingent on continued service and typically convert to ordinary shares as they vest.
• Because this is a grant (not a buy or sell), it should be viewed as executive compensation rather than a direct market sentiment signal.